Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2014; 20(28): 9286-9291
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9286
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9286
Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer
Paul H Sugarbaker, Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, Washington, DC 20010, United States
Author contributions: Sugarbaker PH wrote the paper.
Correspondence to: Paul H Sugarbaker, MD, FACS, FRCS, FASAS, Chief, Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, United States. paul.sugarbaker@medstar.net
Telephone: +1-202-8773908 Fax: +1-202-8778602
Received: October 19, 2013
Revised: February 15, 2014
Accepted: April 5, 2014
Published online: July 28, 2014
Revised: February 15, 2014
Accepted: April 5, 2014
Published online: July 28, 2014
Core Tip
Core tip: The prevention of a disease process has always been superior to the treatment of the same disease throughout the history of medicine and surgery. Local recurrence and peritoneal metastases occur in approximately 8% of colon cancer patients and 25% of rectal cancer patients and should be prevented. If peritoneal metastases are treated along with the primary colon resection, improved 5-year survival was seen. These results are superior to the results of treatment after peritoneal metastases developed as recurrence. A second-look in selected patients has been shown to be effective.